Twinpig Biolab Co., Ltd. (CEO Bae Hyeon-su) announced on the 20th that it has been selected for the 2025 SCALE-UP TIPS R&D project hosted by the Ministry of SMEs and Startups. With this selection, the company will receive up to 1.2 billion won in R&D funding over the next three years to pursue the development of next-generation dual-target antibody-drug conjugates (ADCs) based on the TAMpep platform.
Twinpig Biolab has established itself as a bio startup recognized for its technological prowess and commercial viability, having been selected for government R&D programs, both the existing TIPS and Post-TIPS programs. Utilizing its proprietary TAMpep platform, the company is developing peptide-drug conjugates (PDCs) targeting liver and prostate cancer, as well as TAMpep-ADC-based immuno-oncology agents targeting breast cancer, non-small cell lung cancer, and other cancers.
Additionally, the company is discussing joint development and technology transfer collaborations with global pharmaceutical companies based on its TAMpep technology. This project is expected to enable the advancement of the dual-targeting ADC candidate, T-TB511, currently in development and lay the foundation for global commercialization. T-TB511 is a modular ADC that simultaneously targets HER2-positive cancer cells and M2-TAM, aiming to expand the therapeutic reach to patients with HER2-low susceptibility and those with tumor microenvironment (TME) resistance.
This selection for Scaleup TIPS was based on upfront investment and technology verification by the operator, Scaleup Partners. Scaleup TIPS is a public-private matching program in which the government provides follow-up R&D support to companies recommended by the operator (VC) in which the operator has invested more than KRW 1 billion. Twinpig Biolab has maintained a cooperative relationship with Scaleup Partners since moving into the Seoul Bio Hub in 2020, and Scaleup Partners, highly evaluating the company's technological potential, invested approximately KRW 1.5 billion.
A ScaleUp Partners representative said, “The TAMpep platform has technological advantages that can expand its scope of application to patients with intractable diseases,” and added, “We expect that this project will further enhance the completeness of the candidate substance.”
Bae Hyun-soo, CEO of Twinpig Biolab, said, “The selection of Scale-Up Tips has accelerated the development of TAMpep-based dual-targeting ADCs,” and added, “Based on the supported research and development resources, we will advance our technology and grow it into a world-class precision medicine technology.”
- See more related articles
You must be logged in to post a comment.